Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.73
-0.1400-1.09%
Post-market: 12.800.0700+0.55%19:58 EDT
Volume:2.93M
Turnover:37.10M
Market Cap:1.78B
PE:-3.80
High:12.85
Open:12.64
Low:12.44
Close:12.87
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:0.93
T/O Rate:2.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.45
PE(LYR):-3.34

Loading ...

Stock Track | Intellia Therapeutics Plummets 8.58% Intraday on $150 Million Public Offering Announcement

Stock Track
·
Apr 28

Intellia Therapeutics Inc - Commences $150 Mln Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Apr 28

Press Release: Intellia Announces Proposed Public Offering of Common Stock

Dow Jones
·
Apr 28

Intellia Therapeutics Is Maintained at Neutral by Baird

Dow Jones
·
Apr 28

Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley

TIPRANKS
·
Apr 28

Intellia Therapeutics price target raised to $13 from $7 at Baird

TIPRANKS
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Biogen (BIIB)

TIPRANKS
·
Apr 27

Intellia Therapeutics Shares Jump 8% Premarket After Rare Genetic Disorder Therapy Meets Main Goal in Trial

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Reuters
·
Apr 27

Intellia starts rolling FDA BLA submission for lonvo-z in hereditary angioedema

Reuters
·
Apr 27

Intellia Therapeutics Inc - Single Dose of Lonvo-Z Frees Most Patients From Attacks and Therapy for Six Months

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc: Preparing for a Potential U.S. Launch of Lonvo-Z in First Half of 2027

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - Phase 3 Haelo Trial of Lonvo-Z Meets Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - Initiates Rolling Bla Submission With FDA for Lonvo-Z

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - No Serious Adverse Events Observed With Lonvo-Z in Phase 3 Trial

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (Lonvo-Z) as a One-Time Treatment for Hereditary Angioedema

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Inc - Plans Lonvo-Z Commercial Launch in First Half of 2027 IF Approved

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Stock Track | Intellia Therapeutics Soars 33.46% in Pre-Market on Analyst Buy Rating and Lonvo-z Phase 3 Optimism

Stock Track
·
Apr 27

Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained

TIPRANKS
·
Apr 27